The supernatant of Lactiplantibacillus plantarum 25 is more effective than extracellular vesicles in alleviating ulcerative colitis and improving intestinal barrier function

TL;DR

The supernatant from Lactiplantibacillus plantarum 25 is more effective than extracellular vesicles in reducing ulcerative colitis and improving gut barrier function in mice.

Contribution

This study identifies the supernatant of L. plantarum 25 as a more effective therapeutic component than extracellular vesicles for UC treatment.

Findings

LP25 supernatant significantly improved survival and reduced disease severity in UC mice.

Supernatant preserved tight junction proteins and modulated gut microbiota better than EVs.

It inhibited macrophage TLR4/NF-κB activation more effectively than extracellular vesicles.

Abstract

Lactiplantibacillus plantarum (L. plantarum) has been reported to attenuate ulcerative colitis (UC) and restore intestinal barrier integrity. However, it remains unclear whether culture supernatant or extracellular vesicles (EVs) are more effective.

UC was induced in mice to compare the effects of L. plantarum 25 (LP25) supernatant and EVs on disease severity, survival, and tight junction protein expression. Gut microbiota and metabolism were analyzed by 16S rRNA sequencing and untargeted metabolomics. In vitro, LPS-stimulated Caco-2 cells and a Caco-2/RAW 264.7 co-culture model were used to evaluate barrier integrity, immune responses, and TLR4/NF-κB pathway activation.

Compared with EVs, LP25 supernatant significantly improved survival, alleviated disease severity, preserved tight junction protein expression, modulated gut microbiota, enhanced intestinal functional protein expression, and inhibited macrophage TLR4/NF-κB activation.

LP25 supernatant exerts superior protective effects compared with EVs in alleviating UC and maintaining intestinal barrier function, highlighting its potential as a functional component for dietary interventions targeting inflammatory bowel diseases.

Figures